Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s CellSeed, MNCs To Market Cornea Tissue Technique Globally

This article was originally published in PharmAsia News

Executive Summary

Japan's CellSeed and three foreign companies have united to market globally the regenerative cornea replacement tissue CellSeed developed. CellSeed, a spinoff from Tokyo Women's Medical University where the technique was developed, has trials under way in France. The three partners are Teva Pharmaceutical Industries of Israel, Genesis Pharma of Greece and Orphan Australia of Australia, which together plan to market the tissue in more than 12 countries as soon as 2011. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts